The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut ...

Clostridioides difficile is a type of bacteria that often affects people who have been taking antibiotics, GST Micro LLC ...

The panelist discusses Rebyota, a treatment approved by the FDA for preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment for recurrent C difficile ...

Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...

Following the previously announced successful End of Phase 2 Meeting achieving agreement with FDA on non-clinical and clinical Phase 3-readiness, Acurx has now also received written positive feedback ...

The product is based on purified Firmicutes bacterial spores delivered in an oral capsule that is designed to encourage the regrowth of healthy bacteria after antibiotic treatment for C.

A live biotherapeutic, SER-155 secured FDA fast track status in December 2023. SER-155 also supports the decrease of ...

Fintel reports that on December 11, 2024, Wells Fargo initiated coverage of Summit Therapeutics (NasdaqGM:SMMT) with a ...

Current vaccines offer treatment but fail to halt transmission ... New mRNA Vaccine Created to Prevent and Treat C. Difficile Oct. 17, 2024 — A new vaccine provides hope for treating and even ...

When evaluating a patient with RFL, it is important for the clinician to be aware of the etiology and pathophysiology of common causative syndromes, as well as diagnostic procedures and treatment ...

A national watchdog organization recently released its fall 2024 hospital safety grades rating Wichita hospitals on multiple ...